Overview Financials News + Filings Key Docs Ownership Insiders
|
|
Rani Therapeutics Holdings, Inc.
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Mar-05-23 | Dec-05-22 | Jun-30-22 | Mar-31-22 | Mar-05-22 | Dec-31-21 |
| | 10-Q | 10-Q | 8-K | 8-K | 10-Q | 10-Q | 8-K | 8-K |
| Revenues | 0.0 | 0.0 | 9.7 | 10.4 | 0.0 | 0.0 | 7.6 | 7.4 |
| Revenue growth | | | 27.9% | 40.0% | -100.0% | -100.0% | | 3431.9% |
| Cost of goods sold | 0.0 | 0.0 | 19.4 | 17.5 | 0.0 | 0.0 | 15.2 | 13.4 |
| Gross profit | 0.0 | 0.0 | -9.7 | -7.1 | 0.0 | 0.0 | -7.6 | -5.9 |
| Gross margin | | | -100.0% | -68.3% | | | -100.0% | -80.2% |
| Selling, general and administrative [+] | 7.2 | 6.8 | 6.8 | 7.1 | 6.3 | 6.2 | 6.2 | 5.9 |
| General and administrative | 7.2 | 6.8 | 6.8 | 7.1 | 6.3 | 6.2 | 6.2 | 5.9 |
| Research and development | 11.1 | 9.7 | | | 9.5 | 7.6 | | |
| Other operating expenses | | | | 3.3 | | | | 1.5 |
| EBITDA [+] | -18.1 | -16.3 | | | -15.7 | -13.7 | | |
| EBITDA growth | 15.1% | 19.5% | 19.9% | 30.8% | 189.1% | 156.0% | | 170.3% |
| EBITDA margin | | | -170.1% | -168.3% | | | -181.5% | -180.2% |
| Depreciation and amortization | 0.2 | 0.2 | | | 0.1 | 0.1 | | |
| EBIT [+] | -18.3 | -16.5 | -16.5 | -17.5 | -15.8 | -13.8 | -13.8 | -13.4 |
| EBIT growth | 15.4% | 19.9% | 19.9% | 30.8% | 191.3% | 158.1% | | 170.3% |
| EBIT margin | | | -170.1% | -168.3% | | | -181.5% | -180.2% |
| Interest expense, net [+] | 1.3 | 1.2 | | | | | | 0.0 |
| Interest expense | 1.3 | 1.2 | | | | | | |
| Interest income | | | | | | | | 0.0 |
| Other income (expense), net | 0.9 | 0.9 | -0.3 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax income | -18.7 | -16.8 | -16.8 | -17.4 | -15.8 | -13.8 | -13.8 | -13.3 |
| Income taxes | 0.0 | -8.5 | 0.0 | 0.0 | 0.2 | 0.1 | 0.1 | 0.0 |
| Tax rate | 0.0% | 50.3% | 0.0% | 0.2% | | | | |
| Minority interest | -9.4 | -8.5 | -8.5 | -8.6 | -8.3 | -7.6 | -7.6 | -8.1 |
| Net income | -9.3 | -8.4 | -16.8 | -17.3 | -7.6 | -6.2 | -13.8 | 0.0 |
| Net margin | | | -173.3% | -167.0% | | | -182.2% | 0.0% |
| |
| Basic EPS [+] | ($0.37) | ($0.33) | | | ($0.31) | ($0.29) | | |
| Growth | 17.3% | 14.1% | | | | | | |
| Diluted EPS [+] | ($0.37) | ($0.33) | | | ($0.31) | ($0.29) | | |
| Growth | 17.3% | 14.1% | | | | | | |
| |
| Shares outstanding (basic) [+] | 25.3 | 25.2 | | | 24.4 | 21.4 | | |
| Growth | 4.0% | 17.9% | | | -48.0% | | | |
| Shares outstanding (diluted) [+] | 25.3 | 25.2 | | | 24.4 | 21.4 | | |
| Growth | 4.0% | 17.9% | | | -48.0% | | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|